Company profilePharmaceutical#372 of 1,318 in Pakistan✓ No DRAP alerts

REKO PHARMACAL (PVT) LTD.

Pharmaceutical company · 46 brands · 57 molecules

Ranked #214 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

46 registered products 22 pharmaceutical brands 57 distinct molecules 0 DRAP alerts

Company overview

46
registered products
22
pharmaceutical brands
57
distinct molecules
12
therapeutic classes
0
DRAP alerts

REKO PHARMACAL (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 46 product registrations across 57 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Neuro. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Neuro · 2Other Beta-Lactam, Cephalosporins & Penems · 2Quinolone Antibacterials · 2Agents Against Amoebiasis And Other Protozoal Diseases · 2Aminoglycoside Antibacterials · 1Cardiac Therapy · 1Corticosteroid, Plain · 1Antiepileptics · 1Opioids · 1Cough Suppressants And Expectorants, Combinations · 1Anti-Infective, Ophthalmologicals · 1

Conditions treated

Epilepsy/Convulsion · 1Alzheimer`S · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO2 products · Rs 338.33 – Rs 2,736
Servaid3 products · Rs 900 – Rs 2,912.1
Median across source: Rs 1,537.16

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for REKO

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.